secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001867096-26-000010
Event type: litigation
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma sues Torrent, Somerset over Recorlev patent infringement
------------------------------------------------------------------------

- Filed Hatch-Waxman lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over ANDA for generic Recorlev.
- Lawsuit alleges infringement of four Orange Book patents expiring March 2040 (U.S. Patent Nos. 11,020,393, 11,278,547, 11,903,940, 12,377,096).
- Seeks injunction to block generic competition until patent expiry in March 2040.
- Recorlev also benefits from Orphan Drug Exclusivity through December 2028.
- CEO John P. Shannon cites confidence in IP and intention to vigorously defend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000010/0001867096-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000010/xers-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer